Eledon Pharmaceuticals, Inc. Operating Income

Quick Answer

Eledon Pharmaceuticals, Inc. reported Operating Income of -$43.00 million for fiscal year 2023.

Eledon Pharmaceuticals, Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2023 -$43.00M +51.4%
2022 -$88.43M -139.9%
2021 -$36.87M -99.7%
2020 -$18.46M -15.0%
2019 -$16.05M -14.2%
2018 -$14.06M -7.2%
2017 -$13.12M -155.9%
2016 -$5.13M +88.7%
2015 -$45.26M -92.9%
2014 -$23.46M -49.0%
2013 -$15.75M -63.2%
2012 -$9.65M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$19.07M +7.0% +22.9%
June 30, 2025 -$24.73M -70.5% -37.7%
March 31, 2025 -$17.96M -65.3% +12.4%
September 30, 2024 -$20.51M -83.2% -41.4%
June 30, 2024 -$14.50M -40.1% -33.4%
March 31, 2024 -$10.87M +2.2% +2.9%
September 30, 2023 -$11.20M -5.7% -8.2%
June 30, 2023 -$10.35M -11.5% +6.8%
  • Eledon Pharmaceuticals, Inc. showed an increase of +51.4% in Operating Income compared to the prior fiscal year.
  • Over the 2012–2023 period, Eledon Pharmaceuticals, Inc.’s operating income has declined by 345.6% (from -$9.65 million to -$43.00 million).
  • The most recent figure is from Eledon Pharmaceuticals, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 28, 2024.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment